Do We Get Samples of the Report?

Yes, you will receive a sample copy of the market research report from the sales team when you put a query to us. The sample report is free and offers a brief view of the report and information on data available before you purchase the full-fledged report. Also, we will provide a demo sample for any oncoming study.

How to Buy a Market Report?

Select the report you wish to purchase and proceed to buy it by making an online payment. We use a secured gateway for payment transfers and do not share your financial information with any unconcerned third party.

In Which Format Will I Get the Report?

The report will be delivered in spreadsheet and PDF format. In some cases, PPT formats could be available as well.

In How Much Time I will Get the Report After Purchase?

After confirmation of the payment, you will receive the electronic format of the report at your registered email address in (mention the timeline for the delivery). If you buy a report over a holiday or weekend, we will process the request the next working day.

How Can I Get the Report Customized?

Market studies and reports already contain important data and are ready for distribution to the purchaser. However, if there is any particular query, addition, or customization you require, then contact us on our email id or phone. We will look to accommodate your request and see what can be done at the earliest. The research team will design the report accordingly and discuss the solutions beforehand with you.

How Much Will It Cost to Get a Report Customized?

The price of the customized report will be conveyed to you by our team after we agree on the deliverable. A delivery timeline will be set so that you get the report within the expected date. Any requests for customizations after selling the report will be handled by a separate department and the prices for the same mentioned upfront.

Can I Buy Only a Particular Segment of the Study?

While usually such a request is not accommodated as any market research report is wholesome and the cost of the report is for overall contents, in special cases, we may be able to sell select segments of the report based on your requirements.

Is There Any Available Discount?

Our team will love to support academicians, start-ups, students, and others with consulting and research. Thus, our pricing plan is based on keeping these interests in mind and is already affordable. However, we may have discounts available for particular customer types and reports. So, contact us for more information.

Which Services Are Complimentary Before Purchasing the Report?

We have consumer-centric reports and offer several facilities before selling. You will get a free review and sample report, talk to our customer care team for any additions to be done and meet special requirements, and interact with our analysts for deeper understanding.

Will I Receive a Bill or Invoice for the Report Purchased?

Yes, you will get an invoice for the purchase you made. The invoice will be sent to you electronically on your registered email id.

What If I am Unable to Find the Report in the Catalog?

We have a vast database of market reports and studies and there are a few which may not have been uploaded yet. If you are unable to find the one you want, then get in touch with our sales team by phone or email and we will connect with you for assistance.

How Often Are the Existing Studies Updated?

Not every study is the same. Thus, the update for reports will depend on the ongoing research and changes if any to be incorporated in the document or not.

What If the Report Does Not Contain the Information I Want?

The market research reports are constructed keeping in mind the industry trends, nature of the study, and required inputs. But if you want something more than what is stated in the report, we can help you out with further research if possible. Contact us right away, and we will do the needful to aid you.

Is the Payment Refundable?

Once the payment is done, it is non-refundable because as per the standard policy, the utility of the reports is based on knowledge sharing, and thus, a refund is not possible to make after we have issued you obtain the study. To avoid the hassle, we have a detailed view of the report and its ideas through a sample report.

What If the Payment Fails?

If the payment fails then be assured that you shall receive the money back to the source payment mode from the payment gateway. Aarkstore is not responsible for any loss of payment in the process.

Can I Avail the Report of a Particular Country/Region?

Yes, we can provide a report or segment related to a particular region or geography if we have that feature available for the document.

Do You Offer Support After Purchase?

Yes, we are here to solve any queries you may have for the report from our analyst till a given timeframe. To understand more about this, get in touch with us.

Myocardial Fibrosis - Pipeline Review, H2 2017

DESCRIPTION

TABLE OF CONTENTS

RELATED REPORTS

SAMPLE REQUEST

REVIEWS

DESCRIPTION

Myocardial Fibrosis - Pipeline Review, H2 2017

Summary

The latest Pharmaceutical and Healthcare disease pipeline guide Myocardial Fibrosis - Pipeline Review, H2 2017, provides an overview of the Myocardial Fibrosis (Cardiovascular) pipeline landscape.

Myocardial fibrosis is an abnormal thickening of the heart valves due to inappropriate proliferation of cardiac fibroblasts. Symptoms include chest pain, some abdominal swelling, nausea and fatigue.

Report Highlights

The Pharmaceutical and Healthcare latest pipeline guide Myocardial Fibrosis - Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Myocardial Fibrosis (Cardiovascular), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Myocardial Fibrosis (Cardiovascular) pipeline guide also reviews of key players involved in therapeutic development for Myocardial Fibrosis and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 10 and 4 respectively. Similarly, the Universities portfolio in Preclinical stages comprises 3 molecules, respectively.

Myocardial Fibrosis (Cardiovascular) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Scope
- The pipeline guide provides a snapshot of the global therapeutic landscape of Myocardial Fibrosis (Cardiovascular).
- The pipeline guide reviews pipeline therapeutics for Myocardial Fibrosis (Cardiovascular) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Myocardial Fibrosis (Cardiovascular) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Myocardial Fibrosis (Cardiovascular) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Myocardial Fibrosis (Cardiovascular)

Reasons to buy
- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Myocardial Fibrosis (Cardiovascular).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Myocardial Fibrosis (Cardiovascular) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

TABLE OF CONTENTS

List of Tables 5
List of Figures 5
Introduction 6
Global Markets Direct Report Coverage 6
Myocardial Fibrosis - Overview 7
Myocardial Fibrosis - Therapeutics Development 8
Pipeline Overview 8
Pipeline by Companies 9
Pipeline by Universities/Institutes 10
Products under Development by Companies 11
Products under Development by Universities/Institutes 12
Myocardial Fibrosis - Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Myocardial Fibrosis - Companies Involved in Therapeutics Development 21
Daewoong Pharmaceutical Co Ltd 21
Evotec AG 21
Galectin Therapeutics Inc 22
Invivosciences Inc 22
Lead Discovery Center GmbH 22
MandalMed Inc 23
Merck & Co Inc 23
Miragen Therapeutics Inc 24
Palatin Technologies Inc 24
ProMetic Life Sciences Inc 25
Sarfez Pharmaceuticals Inc 25
TRACON Pharmaceuticals Inc 26
Myocardial Fibrosis - Drug Profiles 27
BMP-7 - Drug Profile 27
Product Description 27
Mechanism Of Action 27
R&D Progress 27
carotuximab - Drug Profile 29
Product Description 29
Mechanism Of Action 29
R&D Progress 29
Drugs for Tissue Fibrosis - Drug Profile 41
Product Description 41
Mechanism Of Action 41
R&D Progress 41
DWN-10290 - Drug Profile 42
Product Description 42
Mechanism Of Action 42
R&D Progress 42
GRMD-02 - Drug Profile 43
Product Description 43
Mechanism Of Action 43
R&D Progress 43
Monoclonal Antibodies to Inhibit Marinobufagenin for Cardiovascular Diseases - Drug Profile 57
Product Description 57
Mechanism Of Action 57
R&D Progress 57
MRG-201 - Drug Profile 58
Product Description 58
Mechanism Of Action 58
R&D Progress 58
NM-922 - Drug Profile 61
Product Description 61
Mechanism Of Action 61
R&D Progress 61
PBI-4050 - Drug Profile 62
Product Description 62
Mechanism Of Action 62
R&D Progress 62
PL-5028 - Drug Profile 71
Product Description 71
Mechanism Of Action 71
R&D Progress 71
PN1-Ab - Drug Profile 72
Product Description 72
Mechanism Of Action 72
R&D Progress 72
Recombinant Protein to Inhibit Galectin-3 for Myocardial Fibrosis and Oncology - Drug Profile 73
Product Description 73
Mechanism Of Action 73
R&D Progress 73
Small molecules to Inhibit CYP11B2 for Cardiovascular Diseases - Drug Profile 74
Product Description 74
Mechanism Of Action 74
R&D Progress 74
Small Molecules to Inhibit RhoGEF12 for Cardiovascular Diseases - Drug Profile 75
Product Description 75
Mechanism Of Action 75
R&D Progress 75
SP-20102 - Drug Profile 76
Product Description 76
Mechanism Of Action 76
R&D Progress 76
Synthetic Peptides to Agonize AGTR2 for Kidney Fibrosis, Liver Fibrosis and Myocardial Fibrosis - Drug Profile 77
Product Description 77
Mechanism Of Action 77
R&D Progress 77
TPI-2049 - Drug Profile 78
Product Description 78
Mechanism Of Action 78
R&D Progress 78
TRC-205 - Drug Profile 79
Product Description 79
Mechanism Of Action 79
R&D Progress 79
VB-0004 - Drug Profile 80
Product Description 80
Mechanism Of Action 80
R&D Progress 80
Myocardial Fibrosis - Dormant Projects 81
Myocardial Fibrosis - Product Development Milestones 82
Featured News & Press Releases 82
Oct 29, 2015: ProMetics PBI-4050 Cleared to Commence Clinical Trial in Patients With Type 2 Diabetes and Multi-Organ Fibrosis in Europe 82
Aug 05, 2014: Galectin Therapeutics Receives U.S. Patent for GR-MD-02 Composition of Matter 82
Appendix 84
Methodology 84
Coverage 84
Secondary Research 84
Primary Research 84
Expert Panel Validation 84
Contact Us 84
Disclaimer 85

List Of Tables

List of Tables
Number of Products under Development for Myocardial Fibrosis, H2 2017 8
Number of Products under Development by Companies, H2 2017 9
Number of Products under Development by Universities/Institutes, H2 2017 10
Products under Development by Companies, H2 2017 11
Products under Development by Universities/Institutes, H2 2017 12
Number of Products by Stage and Target, H2 2017 14
Number of Products by Stage and Mechanism of Action, H2 2017 16
Number of Products by Stage and Route of Administration, H2 2017 18
Number of Products by Stage and Molecule Type, H2 2017 20
Myocardial Fibrosis - Pipeline by Daewoong Pharmaceutical Co Ltd, H2 2017 21
Myocardial Fibrosis - Pipeline by Evotec AG, H2 2017 22
Myocardial Fibrosis - Pipeline by Galectin Therapeutics Inc, H2 2017 22
Myocardial Fibrosis - Pipeline by Invivosciences Inc, H2 2017 22
Myocardial Fibrosis - Pipeline by Lead Discovery Center GmbH, H2 2017 23
Myocardial Fibrosis - Pipeline by MandalMed Inc, H2 2017 23
Myocardial Fibrosis - Pipeline by Merck & Co Inc, H2 2017 24
Myocardial Fibrosis - Pipeline by Miragen Therapeutics Inc, H2 2017 24
Myocardial Fibrosis - Pipeline by Palatin Technologies Inc, H2 2017 25
Myocardial Fibrosis - Pipeline by ProMetic Life Sciences Inc, H2 2017 25
Myocardial Fibrosis - Pipeline by Sarfez Pharmaceuticals Inc, H2 2017 25
Myocardial Fibrosis - Pipeline by TRACON Pharmaceuticals Inc, H2 2017 26
Myocardial Fibrosis - Dormant Projects, H2 2017 81

RELATED REPORTS

SAMPLE REQUEST

Fill The Form For Sample Request

Full Name*

Business Email *

E-mail

Country *

Contact No *

Alternate No

Note : * Kindly provide us with your company id and get the sample reports at the earliest.

REVIEWS

There is no Reviews available

Search and Get the Latest Market Research Reports

Myocardial Fibrosis - Pipeline Review, H2 2017

Myocardial Ischemia (Cardiovascular) - Drugs In Development, 2021

Myocardial Infarction Global Clinical Trials Review, H1, 2020

Pulmonary Fibrosis - Global Clinical Trials Review, H2, 2021

Myelofibrosis - Pipeline Insight, 2021

FAQs